Saama, a leading provider of AI-based solutions for accelerating clinical development and commercialization, has recently signed a new agreement with AstraZeneca, a global biopharmaceutical leader. This multi-year agreement aims to streamline and enhance AstraZeneca’s clinical data management and medical review processes by leveraging Saama’s AI-enabled technology platform. The goal is to set a new industry standard for accelerating drug development and ultimately bring much-needed treatments to patients faster. By integrating Saama’s platform into its systems, AstraZeneca will benefit from faster clinical database lock, more efficient data reviews, and smarter medical review processes. This collaboration highlights the shared commitment of both companies to redefine drug development paradigms for the benefit of patients worldwide.
Saama Signs New Agreement with AstraZeneca for AI-Driven Drug Development
Overview of the Agreement
Saama, a leading provider of AI-based solutions for clinical development and commercialization, has announced a multi-year agreement with global biopharmaceutical leader AstraZeneca. The purpose of this agreement is to streamline and facilitate AstraZeneca’s clinical data management and medical review processes using Saama’s AI-enabled technology platform. The ultimate goal is to set a new industry standard for accelerating clinical development.
Saama’s AI-Enabled Technology Platform
Saama’s AI-based solutions are designed to revolutionize the clinical development process. By leveraging advanced artificial intelligence technologies, Saama’s platform can significantly accelerate the speed at which drugs are developed and brought to market. This aligns with Saama’s vision of bringing much-needed treatments to patients sooner. Saama and AstraZeneca share a common commitment to redefine traditional drug development paradigms and embrace innovative, cutting-edge technologies.
AstraZeneca’s Integration of Saama’s Platform
Under this new agreement, AstraZeneca will integrate Saama’s platform into its existing data management and review systems. Specifically, AstraZeneca will utilize Saama’s Smart Data Quality (SDQ), Data Hub, and Patient Insights solutions. By doing so, AstraZeneca aims to achieve faster clinical database lock, more efficient data reviews, and smarter medical review processes. This integration of Saama’s platform will modernize AstraZeneca’s data and medical review processes, promoting automation, simplification, and the exploitation of AI for new insights.
Benefits of Saama’s Platform
Saama’s platform offers numerous benefits that contribute to the modernization of data and medical review processes. By automating various tasks, streamlining data flows, and harnessing the power of artificial intelligence, Saama’s solutions can provide valuable efficiency gains and generate new insights. Ultimately, Saama’s platform is expected to deliver medical advances that will benefit patients worldwide. By embracing Saama’s technology, AstraZeneca is positioning itself at the forefront of the industry, leading the way in driving innovation and improving patient outcomes.
Commitment to Transform Clinical Development Processes
Data review is a crucial aspect of clinical trials, as it ensures the validity and reliability of study results. Saama is committed to helping companies transform their clinical development processes by offering groundbreaking solutions that set new industry benchmarks. By partnering with AstraZeneca, Saama is further solidifying its commitment to revolutionize drug development and pave the way for a more efficient and effective clinical trial landscape.
Saama’s Solutions for Clinical Trial Data
Saama’s suite of solutions, including Smart Data Quality (SDQ), Data Hub, and Patient Insights, are specifically designed to handle the high volume and variety of clinical trial data. Leveraging advanced technology and AI capabilities, Saama’s platform centralizes and standardizes data from multiple sources. This streamlines medical review processes, enhances patient safety oversight, predicts participant behavior, and accelerates the discovery of clinical signals. Saama’s solutions enable study teams to effectively manage and analyze complex clinical data, ensuring reliable and meaningful insights.
Saama’s Support for the Full Spectrum of Clinical Development
Saama’s AI-enabled SaaS solutions are designed to support all stages of the clinical development process. Whether it’s patient safety oversight or clinical signal discovery, Saama’s platform provides valuable tools and capabilities that empower study teams to make informed decisions and drive successful outcomes. With its comprehensive range of applications, Saama’s platform is an invaluable asset for pharmaceutical companies looking to optimize their clinical development processes.
About Saama
Saama is a recognized leader in the development of life science solutions that accelerate the delivery of therapies to patients. With a focus on leveraging innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. Saama’s headquarters are located in Campbell, California, but the company has a global presence, with employees around the world. Through its cutting-edge solutions and unwavering commitment to saving and improving lives, Saama is revolutionizing the pharmaceutical industry.
Contact Information
For more information about Saama and its AI-enabled technology platform, visit saama.com.
Conclusion
The new agreement between Saama and AstraZeneca marks a significant milestone in the advancement of AI-driven drug development. By integrating Saama’s platform into its data management and review systems, AstraZeneca is embracing innovation and setting a new industry standard. Saama’s solutions offer substantial benefits, including automation, streamlined data flows, and AI-driven insights. With its commitment to transforming clinical development processes, Saama is at the forefront of driving change in the pharmaceutical industry. To learn more about Saama’s platform and services, visit their website and discover how they are shaping the future of drug development.
